{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T19:39:40Z","timestamp":1771529980268,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,29]],"date-time":"2015-05-29T00:00:00Z","timestamp":1432857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Brasileira de Hematologia e Hemoterapia"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.bjhh.2015.03.017","type":"journal-article","created":{"date-parts":[[2015,6,7]],"date-time":"2015-06-07T10:23:40Z","timestamp":1433672620000},"page":"277-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Primary nodal peripheral T-cell lymphomas: diagnosis and therapeutic considerations"],"prefix":"10.1016","volume":"37","author":[{"given":"Luis Alberto de P\u00e1dua Covas","family":"Lage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara Carvalho dos Santos","family":"Cabral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata de Oliveira","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne de Castro","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debora","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cl\u00e1udia Nogueira","family":"Zerbini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.bjhh.2015.03.017_bib0205","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/modpathol.2012.181","article-title":"Peripheral T-cell NK-cell lymphomas in the WHO classification: pearls and pitfalls","volume":"26","author":"Jaffe","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.bjhh.2015.03.017_bib0210","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/asheducation-2006.1.317","article-title":"Pathobiology of peripheral T-cell lymphomas","author":"Jaffe","year":"2006","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"issue":"25","key":"10.1016\/j.bjhh.2015.03.017_bib0215","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bjhh.2015.03.017_bib0220","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.mpdhp.2009.12.004","article-title":"T- and NK-cell lymphoma update","volume":"16","author":"Dogan","year":"2009","journal-title":"Diagn Histopathol"},{"issue":"4","key":"10.1016\/j.bjhh.2015.03.017_bib0225","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2005-03-1306","article-title":"T-cell non-Hodgkin lymphoma","volume":"107","author":"Rizvi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bjhh.2015.03.017_bib0230","doi-asserted-by":"crossref","first-page":"624040","DOI":"10.1155\/2010\/624040","article-title":"Peripheral T-cell lymphoma: review and updates of current management strategies","volume":"2010","author":"Tang","year":"2010","journal-title":"Adv Hematol"},{"issue":"5","key":"10.1016\/j.bjhh.2015.03.017_bib0235","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-2141.2009.08003.x","article-title":"Advances in the understanding and management of angioimmunoblastic T-cell lymphoma","volume":"148","author":"Leval","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.bjhh.2015.03.017_bib0240","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1309\/R2Q9CCUVTLRYCF3H","article-title":"Anaplastic large cell lymphoma","volume":"127","author":"Medeiros","year":"2007","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.bjhh.2015.03.017_bib0245","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/hon.897","article-title":"Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma","volume":"27","author":"Fornari","year":"2009","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.bjhh.2015.03.017_bib0250","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.1331","article-title":"ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects \u2013 a review","volume":"200","author":"Ten Berge","year":"2003","journal-title":"J Pathol"},{"key":"10.1016\/j.bjhh.2015.03.017_bib0255","series-title":"World Health Organization classification: tumors of hematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"issue":"7","key":"10.1016\/j.bjhh.2015.03.017_bib0260","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/PAS.0b013e31802d68e9","article-title":"Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression","volume":"31","author":"Attygalle","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.bjhh.2015.03.017_bib0265","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2559.2007.02632.x","article-title":"Distinguishing angioimmunoblastic T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics","volume":"50","author":"Attygalle","year":"2007","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.bjhh.2015.03.017_bib0270","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1365-2141.2008.07534.x","article-title":"Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma","volume":"144","author":"Konstantinou","year":"2009","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.bjhh.2015.03.017_bib0275","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2141.2008.07042.x","article-title":"Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma","volume":"141","author":"Nelson","year":"2008","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.bjhh.2015.03.017_bib0280","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.critrevonc.2012.02.005","article-title":"Anaplastic large cell lymphoma ALK-positive","volume":"83","author":"Ferreri","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.bjhh.2015.03.017_bib0285","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdq359","article-title":"Comparison of four prognostic scores in peripheral T-cell lymphoma","volume":"22","author":"Guti\u00e9rrez-Garc\u00eda","year":"2011","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.bjhh.2015.03.017_bib0290","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1023\/A:1008418727472","article-title":"Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL classification","volume":"9","author":"L\u00f3pez-Guillermo","year":"1998","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.bjhh.2015.03.017_bib0295","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.bjhh.2015.03.017_bib0300","first-page":"2472","article-title":"Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score","volume":"24","author":"Went","year":"2006","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.bjhh.2015.03.017_bib0305","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.811.811","article-title":"International peripheral T-cell lymphoma (PTCL) clinical and pathology review project: poor outcome by prognostic indices and lack of efficacy with anthracyclines","volume":"106","author":"Vose","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bjhh.2015.03.017_bib0310","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.23144","article-title":"The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification and management","volume":"87","author":"Armitage","year":"2012","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.bjhh.2015.03.017_bib0315","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2011.08651.x","article-title":"Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphomas)","volume":"153","author":"Dearden","year":"2011","journal-title":"Br J Haematol"},{"issue":"1\u20132","key":"10.1016\/j.bjhh.2015.03.017_bib0320","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/10428199609045720","article-title":"Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high grade B-cell lymphomas","volume":"24","author":"Karakas","year":"1996","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"10.1016\/j.bjhh.2015.03.017_bib0325","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin's Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bjhh.2015.03.017_bib0330","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1358\/dot.2013.49.10.2025391","article-title":"Current treatment and future prospects for peripheral T-cell lymphoma","volume":"49","author":"Eyre","year":"2013","journal-title":"Drugs Today (Barc)"},{"issue":"2","key":"10.1016\/j.bjhh.2015.03.017_bib0335","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000353778","article-title":"Autologous stem cell transplantation as the first line treatment for peripheral T-cell lymphoma: results of a comprehensive meta-analysis","volume":"131","author":"Yin","year":"2014","journal-title":"Acta Haematol"},{"issue":"25","key":"10.1016\/j.bjhh.2015.03.017_bib0340","first-page":"3093","article-title":"Up front autologous stem cell transplantation in peripheral T-cell lymphoma: NGL-T-01","volume":"30","author":"d\u2019Amore","year":"2012","journal-title":"J Clin Orthod"},{"issue":"1","key":"10.1016\/j.bjhh.2015.03.017_bib0345","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2012.03.011","article-title":"The role of high dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: a review of the literature and new perspectives","volume":"39","author":"Yared","year":"2013","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.bjhh.2015.03.017_bib0350","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.blre.2007.03.001","article-title":"Peripheral T-cell Lymphomas","volume":"21","author":"Savage","year":"2007","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.bjhh.2015.03.017_bib0355","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.beha.2013.04.005","article-title":"Treatment strategies for peripheral T-cell lymphomas","volume":"26","author":"Foss","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"10.1016\/j.bjhh.2015.03.017_bib0360","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.bjhh.2015.03.017_bib0365","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/sj.bjc.6601011","article-title":"Increased sensivity to gemcitabine of p-glycoproteinand multidrug resistance-associated protein-overexpressing human cancer cell lines","volume":"88","author":"Bergman","year":"2003","journal-title":"Br J Cancer"},{"issue":"18","key":"10.1016\/j.bjhh.2015.03.017_bib0370","first-page":"2190","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.bjhh.2015.03.017_bib0375","series-title":"ASH Annual Meeting Abstracts, vol. 118","first-page":"95","article-title":"Phase II trial of alisertib (MLN8237), an investigational, potent inhibitor of aurora A kinase (AAK), in patients with aggressive B- and T-cell non-Hodgkin lymphoma","author":"Friedberg","year":"2011"},{"issue":"2 Suppl. 2","key":"10.1016\/j.bjhh.2015.03.017_bib0380","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1053\/j.seminhematol.2005.12.008","article-title":"Role of single agent analogues in therapy of peripheral T-cell lymphomas","volume":"43","author":"Dearden","year":"2006","journal-title":"Semin Hematol"},{"issue":"9","key":"10.1016\/j.bjhh.2015.03.017_bib0385","first-page":"1182","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J Clin Orthod"},{"issue":"21","key":"10.1016\/j.bjhh.2015.03.017_bib0390","first-page":"3937","article-title":"The combination of histone deacetylase inhibitors and hypomethylating agents exhibits marked synergy in preclinical models of T-cell lymphomas","volume":"116","author":"Marchi","year":"2013","journal-title":"Blood (ASH Annu Meet Abstract)"},{"issue":"22","key":"10.1016\/j.bjhh.2015.03.017_bib0395","first-page":"1657","article-title":"Final results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL)","volume":"114","author":"Pierkarz","year":"2009","journal-title":"Blood (ASH Annu Meet Abstr)"},{"issue":"19","key":"10.1016\/j.bjhh.2015.03.017_bib0400","first-page":"2764","article-title":"Phase I-II study of an anti-CD30 antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma","volume":"25","author":"Ansell","year":"2007","journal-title":"J Clin Orthod"}],"container-title":["Revista Brasileira de Hematologia e Hemoterapia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1516848415000870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1516848415000870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T04:14:34Z","timestamp":1599106474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1516848415000870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S1516848415000870"],"URL":"https:\/\/doi.org\/10.1016\/j.bjhh.2015.03.017","relation":{},"ISSN":["1516-8484"],"issn-type":[{"value":"1516-8484","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary nodal peripheral T-cell lymphomas: diagnosis and therapeutic considerations","name":"articletitle","label":"Article Title"},{"value":"Revista Brasileira de Hematologia e Hemoterapia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjhh.2015.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}